Volume: 9 Issue: 2
Year: 2021, Page: 73-76, Doi: https://doi.org/10.47799/pimr.0902.16
Received: Feb. 25, 2021 Accepted: April 20, 2021 Published: April 20, 2021
Introduction: Ibutilide is a class 3 antiarrythmic agent that is used infrequently. There are few studies on its usage, especially among Indians.
Materials & Methods: A retrospective study was conducted on patients in a tertiary care unit who had recently developed atrial fibrillation and were given the normal dose of ibutilide. During the study period, data was gathered from medical records.
Results: During the study period, ibutilide was given to a total of 40 patients who met the inclusion criteria. The majority of the participants were under 60 years old and had only been in atrial fibrillation for less than 24 hours. In 70% of cases, atrial fibrillation could be successfully terminated with only a small risk of adverse events.
Conclusion: Ibutilide is a safe and effective treatment for people who have recent onset atrial fibrillation.
Keywords:
1. Vogiatzis I, Papavasiliou E, Dapcevitch I, Pittas S, Koulouris E. Vernakalant versus ibutilide for immediate conversion of recent-onset atrial fibrillation. Hippokratia. 2017;21(2):67-73.
2. Viktorsdottir O, Henriksdottir A, Arnar DO. Ibutilide for treatment of atrial fibrillation in the emergency department. Emerg Med J. 2006;23(2):133-134. doi:10.1136/emj.2004.021394
3. Dilaveris P, Synetos A, Giannopoulos G, Gialafos E, Stefanadis C. Conversion of recent-onset atrial fibrillation or flutter with amiodarone after ibutilide has failed: a rapid, efficient, and safe algorithm. Ann NoninvasiveElectrocardiol. 2005;10(3):382-386. doi:10.1111/j.1542-474X.2005.00646.x
4. Lévy S. Pharmacologic management of atrial fibrillation: current therapeutic strategies. Am Heart J 2001;141:S15– 21.
5. Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995;92:1954–68.
6. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825–33.
7. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834–40.
8. Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659–66.
9. Bharati S, Lev M. Histology of the normal and diseased atrium. In: Falk RH, Podrid PJ, eds. Atrial fibrillation: mechanisms and management. New York: Raven Press, 1992.
10. Falk RH. Atrial fibrillation. N Engl J Med 2001;344:1076– 8.
11. Kopecky SL, Gersh BJ, McGoon MD, et al. Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk. Arch Intern Med 1999;159:1118–22
12. Prystowsky EN, Margiotti R, Fogel RI, et al. Atrial fibrillation with and without heart disease: clinical characteristics and proarrhythmia risk. Circulation 1996;94:I–191.
13. Nair M, George LK, Koshy SK. Safety and efficacy of ibutilide in cardioversion of atrial flutter and fibrillation. J Am Board Fam Med. 2011 Jan-Feb;24(1):86-92. doi: 10.3122/jabfm.2011.01.080096. PMID: 21209348.
Maddela S, Sk.Khasim,Kasturi RR, Arramraju SK , Mudgalkar N, Baviskar A.Efficacy of Ibutilide for Terminating Recent Onset Atrial Fibrillation- A Single Centre Study. Perspectives in Medical Research 2021; 9 (2):73-76 DOI:10.47799/pimr.0902.16